1. Home
  2. BLIN vs BIAF Comparison

BLIN vs BIAF Comparison

Compare BLIN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgeline Digital Inc.

BLIN

Bridgeline Digital Inc.

HOLD

Current Price

$0.91

Market Cap

12.1M

Sector

Technology

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$9.30

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLIN
BIAF
Founded
2000
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
9.2M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
BLIN
BIAF
Price
$0.91
$9.30
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.62
N/A
AVG Volume (30 Days)
51.7K
7.3M
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,568,000.00
$7,900,000.00
Revenue This Year
$22.67
$20.95
Revenue Next Year
$21.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$0.69
$0.24
52 Week High
$1.59
$20.35

Technical Indicators

Market Signals
Indicator
BLIN
BIAF
Relative Strength Index (RSI) 31.31 60.90
Support Level $0.82 $1.27
Resistance Level $0.93 N/A
Average True Range (ATR) 0.05 1.90
MACD -0.00 0.56
Stochastic Oscillator 5.79 46.11

Price Performance

Historical Comparison
BLIN
BIAF

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: